By David Mittleman

Johnson & Johnson to Pay $2.2 Billion to Feds

Federal prosecutors have reached an agreement with Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson, that the company will pay $2.2 billion for allegations that it illegally marketed its drug Risperdal for elderly patients with dementia. According to the fed’s claims, Janssen was not supposed to market its drug to dementia patients from its labeled use to treat Schizophrenia. Janssen marketing messages apparently focused on “behavioral disturbances associated with dementia” that had nothing to do with psychosis. Janssen also allegedly downplayed clinical data showing an …read more